Cortexyme to participate at 4th international conference on porphyromonas gingivalis and related species in oral and systemic diseases

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at the 4th international conference on porphyromonas gingivalis and related species in oral and systemic diseases (pglouisville2022) taking place may 15-17, 2022 in louisville, kentucky. cortexyme's clinical advisory board member
QNCX Ratings Summary
QNCX Quant Ranking